SINTX Technologies, Inc. - Q1 2026 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended March 31, 2026. SINTX Technologies, Inc. is an advanced ceramics company developing silicon nitride-based solutions for medical (biomedical, antipathogenic) and industrial applications. The company operates as a single segment and is classified as a non-accelerated filer and smaller reporting company. As of May 8, 2026, there were 4,319,279 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $380,000 | $369,000 |
| Gross Profit | $144,000 | $123,000 |
| Net Loss | $(2,821,000) | $(2,292,000) |
| Net Loss Per Share (Basic/Diluted) | $(0.70) | $(1.29) |
| Cash and Cash Equivalents (End of Period) | $1,889,000 | $6,500,000 |
| Net Cash Used in Operating Activities | $(2,491,000) | $(1,301,000) |
| Total Debt (Current) | $106,000 | $7,000 |
| Accumulated Deficit | $(294,923,000) | $(284,030,000) |
Material Changes vs. Prior Period
- Revenue: Total revenue increased 3% ($11,000) year-over-year. Excluding the impact of the TA&T subsidiary divestiture in Q1 2025, underlying revenue grew 46%.
- Operating Expenses: Total operating expenses increased 34% to $3.35 million.
- R&D: Decreased 67% ($752,000) due to headcount reductions and reallocation of overhead costs to G&A.
- G&A: Increased 92% ($1.2 million) driven by higher headcount costs ($1.1 million) and the aforementioned overhead reallocation.
- Sales & Marketing: Increased 1,895% ($379,000) due to product launch costs and headcount increases.
- Other Income: Increased 324% to $386,000, primarily due to a $343,000 gain from the change in fair value of derivative liabilities.
- Liquidity: Cash balances decreased by $2.25 million during the quarter. The company utilized $266,000 in proceeds from its At-The-Market (ATM) offering.
Outlook, Risks, and Management Commentary
- Going Concern: Management has concluded that substantial doubt remains regarding the company's ability to continue as a going concern for at least 12 months. Continued operations depend on increasing sales, reducing expenses, and securing additional financing.
- Strategic Focus: The company is shifting resources toward high-growth healthcare sectors, leveraging recent FDA 510(k) clearance for the SiNAPTIC Foot & Ankle Osteotomy Wedge System (October 2025). Revenue from this product was recognized in Q1 2026.
- Capital Resources: The company has an ATM program with $5.7 million remaining capacity (as of March 31, 2026). Subsequent to quarter-end, an additional $0.5 million was sold under the ATM.
- Cost Reduction: The company divested the TA&T subsidiary in February 2025 and subleased the SINTX Armor facility in October 2025, expecting to save approximately $1.0 million over the sublease term.
- Risks: Key risks include the inability to raise additional capital, the need to achieve profitability, and the volatility of derivative liabilities.
Investor Verification Checklist
- Verify the sufficiency of the remaining $5.7 million ATM capacity to fund operations until profitability is achieved.
- Monitor the commercialization progress and revenue contribution of the newly cleared SiNAPTIC Foot & Ankle system.
- Review the trajectory of G&A expenses to ensure the reallocation of costs from R&D does not indicate a permanent structural increase in overhead.
- Assess the impact of the $484,000 derivative liability on future earnings volatility.
- Confirm the timeline for the next potential equity or debt financing round given the "substantial doubt" disclosure.